Characteristics of the Study Population.

<p>HIV-infected persons who initiated antiretroviral therapy (ART), received rifamycin-based anti-tuberculosis therapy while on ART, and did not have tuberculosis at a site of disease that required extended therapy (e g, central nervous system, bone/joint, or pericardium).</p><p>Parentheses include percentages unless otherwise noted.</p><p>TB: tuberculosis</p><p>Baseline CD4+ lymphocyte and HIV-1 RNA measurements were at the time of ART initiation.</p><p>* The proportions of all persons at each study site with TB (the row percentages)—were as follows:</p><p>Argentina: 3%; Brazil: 7%; Chile: 4%; Honduras: 9%; Mexico: 4%; Peru: 16%</p><p>^ Median (IQR) values before tuberculosis diagnosis: 74 (34-191)</p><p># Median (IQR values before tuberculosis diagnosis: 4.4 log₁₀ (2.6-5.2)</p

Risk Factors for Death Among All Tuberculosis Patients.

<p>Cox proportional hazards models of time to death. The models are stratified by study site. Follow-up is from the time of tuberculosis diagnosis. For the multivariable models, missing CD4+ lymphocyte and HIV-1 RNA values were imputed via multiple imputation. Of the 222 subjects, 44 had missing CD4+ lymphocytes and 59 had missing HIV- 1 RNA.</p><p>* Compared to persons starting ART after TB diagnosis</p

Baseline and Treatment Characteristics of the 253 Tuberculosis Patients Included in the Study, According to Length of Follow-up/Survival and Duration of Anti-tuberculosis Therapy.

<p>Data are presented as number (%) except as shown.</p><p>P-values are for the comparison of all 4 groups, using the chi-squared test.</p><p>* the comparison limited to persons with > 6 months of follow-up and known TB treatment duration (the two inner columns) was not statistically significant. If not noted by * the statistical significance of the comparison between these two groups was similar to that of all 4 groups.</p><p>=Data available for 222 patients.</p><p>^ Data available for 222 patients.</p><p># Data available for 171 patients.</p><p>+ Data available for 228 patients.</p><p>a median time between TB diagnosis and ART start: 95 days (IQR: 53, 142)</p><p>b median time between ART start and TB diagnosis: 142 days (IQR: 30, 568)</p

Risk Factors for Death According to Time of ART Start after Tuberculosis Diagnosis.

<p>Cox proportional hazards models. Comparator group is persons starting HAART within the specific timeframe (<u><</u> 60, 90, or 120 days from TB diagnosis). Missing CD4+ lymphocyte values were imputed via multiple imputation.</p><p>Of the 153 persons who started ART after tuberculosis diagnosis, 41 started with 60 days, 71 started within 90 days, and 98 started within 120 days of TB diagnosis. Of the 153 persons, 31 had missing CD4+ lymphocytes.</p